What is the maximum oral dose of Arkamin (clonidine) for an adult?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 3, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Maximum Dose of Arkamin (Clonidine)

The maximum oral dose of clonidine (Arkamin) for adults is 0.8 mg per day, divided into 2 doses. 1

Dosing Guidelines

According to the most recent ACC/AHA hypertension guidelines, oral clonidine dosing ranges from 0.1 to 0.8 mg daily, divided into 2 doses 1. This represents the upper limit for chronic antihypertensive therapy in adults.

Important Dosing Context

  • Standard maintenance dosing: Most patients are controlled on 0.2-0.6 mg daily divided into 2-3 doses
  • Starting dose: Typically 0.1 mg twice daily
  • Titration: Increase gradually by 0.1-0.2 mg per day at weekly intervals

Special Situations

For hypertensive urgencies/emergencies, a different "loading" protocol exists:

  • Initial dose: 0.1-0.2 mg orally
  • Followed by 0.05-0.1 mg hourly until blood pressure controlled
  • Maximum loading dose: 0.5-0.8 mg total 2, 3, 4
  • This achieves blood pressure reduction in approximately 93% of patients within 2-6 hours

Critical Safety Warnings

Never abruptly discontinue clonidine - this can induce hypertensive crisis and rebound hypertension 1. The medication must be tapered gradually over several days to weeks.

Common Pitfalls

  • CNS adverse effects: Clonidine causes significant sedation and dry mouth, particularly at higher doses. These effects are dose-dependent and correlate with plasma concentrations 5
  • Reserved as last-line therapy: Guidelines classify clonidine as a last-line agent due to significant CNS side effects, especially in older adults 1
  • Transdermal alternative: The clonidine patch (0.1-0.3 mg weekly) provides steadier drug release with improved tolerability and may be preferable for adherence 1

Monitoring Requirements

When using doses approaching the maximum:

  • Monitor for excessive sedation and orthostatic hypotension
  • Assess for dry mouth (occurs in majority of patients)
  • Ensure patient understands the critical importance of not missing doses or stopping abruptly
  • Consider transdermal formulation if adherence is questionable

Related Questions

If clonidine is dosed twice daily with one dose at bedtime (HS), when should the second dose be administered?
What is the recommended as‑needed (prn) dosage of clonidine for an adult patient, including adjustments for elderly patients or those with renal or hepatic impairment?
When should clonidine be increased from 0.1 mg to 0.2 mg, and how should the dose be titrated?
Can clonidine 0.1 mg be given to a patient with a blood pressure of 170/90 mmHg?
What is the recommended dosing for clonidine (clonidine) Extended Release (ER) in a patient with a history of hypertension and potential impaired renal function?
I have been taking metformin 1 g extended‑release and dapagliflozin (Forxiga) 10 mg daily for one month without adequate glycemic control; can I continue dapagliflozin 10 mg once daily and add Trajenta Duo (linagliptin 5 mg/metformin 500 mg) twice daily?
Can I switch my 1 g metformin to Trajenta Duo (linagliptin 5 mg/metformin 500 mg) twice daily and keep dapagliflozin 10 mg once daily?
What is the role of antifilarial treatment after hydrocele repair surgery?
What is the appropriate weight‑based IV bolus dosing of tenecteplase for acute massive or submassive pulmonary embolism, including contraindications, monitoring, and follow‑up recommendations?
What medications should be prescribed for a patient with a fasting blood glucose of 203 mg/dL and elevated cholesterol, LDL‑C, and triglycerides?
In a 9‑month‑old male infant with a familial history of similar lesions, presenting with clusters of small, slightly raised, erythematous to skin‑colored papules and dryness on the bilateral lower legs that began at age 4 months, how should this case be evaluated and managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.